Kyntra Bio, Inc. (KYNB) Stock Price & Analysis
Kyntra Bio, Inc. (KYNB) fell 0.38% to USD 6.69 as of June 10, 2026 at 02:25 UTC, according to Nexqual real-time market data.
KYNB last closed at USD 6.72; the session ranged USD 6.67–6.99 on volume of 18,766 shares. Market capitalization is $27.08M, with a 52-week range of USD 4.85–12.6 (NMS). Source: Nexqual, June 10, 2026 at 02:25 UTC.
Key Statistics (as of June 10, 2026 at 02:25 UTC)
| Price | USD 6.69 |
|---|---|
| Change | ▼ 0.38% (down) |
| Previous Close | USD 6.72 |
| Open | USD 6.82 |
| Day Range | USD 6.67 – 6.99 |
| 52-Week Range | USD 4.85 – 12.6 |
| Volume | 18,766 shares |
| Market Cap | $27.08M |
| Exchange | NMS |
Technical Analysis (KYNB)
Nexqual's technical model rates KYNB "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.21 (neutral) |
| vs SMA50 | Below (USD 7) |
| MACD | -0.09 (negative) |
Analyst Ratings (KYNB)
Wall Street analysts rate KYNB "None" based on 1 analysts, with a mean price target of USD 43 (range USD 43–43), per Nexqual as of June 10, 2026 at 02:25 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 43 |
| High Target | USD 43 |
| Low Target | USD 43 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (KYNB)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -3.27 |
| Revenue Estimate | $1.22M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.76 vs est -3.36 ▼ miss |
| 2025-12-31 | USD -3.51 vs est -3.89 ▲ beat |
| 2025-09-30 | USD 49.61 vs est -4.01 ▲ beat |
| 2025-06-30 | USD -1.88 vs est 1 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financials & Fundamentals (KYNB)
| Total Revenue | $7.44M |
|---|---|
| Revenue Growth (YoY) | +36.50% |
| Gross Margin | -275.41% |
| Operating Margin | -369.07% |
| Profit Margin | +2199.42% |
| Current Ratio | 3.61 |
| Total Cash | $87.24M |
| Total Debt | $19.25M |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financial Health Score (KYNB)
Nexqual rates Kyntra Bio, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:25 UTC.
| Growth | Critical — Revenue -97% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $87M cash vs $19M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (KYNB)
| Insider Ownership | +2.03% |
|---|---|
| Institutional Ownership | +25.57% |
| Shares Outstanding | 4.05M |
| Float | 3.56M |
| Short % of Float | +2.93% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Leadership (KYNB)
Kyntra Bio, Inc. is led by Thane Wettig (age 60), CEO & Director, per Nexqual as of June 10, 2026 at 02:25 UTC.
| CEO & Director | Thane Wettig (age 60) |
|---|---|
| Senior VP & CFO | David DeLucia (age 36) |
| Head of People and Culture & Executive Director | Michelle Simonetti |
| Director of IR & Communications - LifeSci Advisors | Gaia Vasiliver-Shamis |
Major Backers & Investors (KYNB)
Notable institutional backers of Kyntra Bio, Inc. include Armistice Capital, LLC, Acadian Asset Management. LLC, Two Sigma Investments, LP, according to Nexqual as of June 10, 2026 at 02:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.88% |
| Acadian Asset Management. LLC | 2.61% |
| Two Sigma Investments, LP | 1.22% |
| HighTower Advisors, LLC | 0.98% |
| Fidelity | 0.9% |
| UBS Group AG | 0.68% |
| Renaissance Technologies | 0.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.4% |
| BlackRock | 2.08% |
| Geode Capital | 1.14% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
From Kyntra Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
- The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
- It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
- The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | USD 9.77 | ▼ 1.51% |
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
| AKBA | Akebia Therapeutics, Inc. | USD 0.92 | ▼ 1.6% |
| AGIO | Agios Pharmaceuticals, Inc. | USD 28.14 | ▼ 0.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:25 UTC. This page is informational and not investment advice.